SCHEMBL4811501

SCHEMBL4811501

O=C(Cc1ccc(O)cc1)N1CCc2cc[c]cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.49
▸ MAPT P10636 5/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ POLB P06746 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ GAA P10253 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ ROCK1 Q13464 1/20 0.42
▸ TSHR P16473 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ NOTUM Q6P988 2/20 0.38
▸ ME2 P23368 2/20 0.38
▸ ME1 P48163 2/20 0.38
▸ ME3 Q16798 2/20 0.38
▸ MAPK1 P28482 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4815197 0.88 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4812759 0.88 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4809337 0.86 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4810685 0.86 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4803446 0.85 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4808688 0.85 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4809914 0.83 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4859975 0.80 TSHR (0.47) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4810712 0.80 MAPT (0.48) ALDH1A1SMN1; SMN2MAPTRAB9APOLB
SCHEMBL4813473 0.79 CYP11B1 (0.54) ALDH1A1SMN1; SMN2MAPTRAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7381734-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2008-06-03 — — US disclosed
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 — — EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 — — US disclosed
EP-1294691-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2006-11-08 — — EP disclosed
US-7074934-B2 An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma TULARIK LIMITED (GB) 2006-07-11 — — US disclosed
US-7067516-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2006-06-27 — — US disclosed
US-20050267173-A1 Serine protease inhibitors LIVELY SARAH E 2005-12-01 — — US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 — — US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 — — US disclosed
US-20040116439-A1 Serine protease inhibitors TULARIK LIMITED (GB) 2004-06-17 — — US disclosed
US-20030216403-A1 Serine protease inhibitors TULARIK LIMITED (GB) 2003-11-20 — — US disclosed
EP-1294691-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-03-26 — — EP disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 — — US disclosed
EP-1240154-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2002-09-18 — — EP disclosed
EP-1192135-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2002-04-03 — — EP disclosed
WO-2001096305-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-12-20 — — WO disclosed
WO-2001044226-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-06-21 — — WO disclosed
WO-2000076970-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 ALDH1A1 2580/4885SMN1; SMN2 3725/4885MAPT 4112/4885
US-20030216403-A1 Serine protease inhibitors SERPINB1, SERPINE1, PRSS1 ALDH1A1 1913/4885SMN1; SMN2 3179/4885MAPT 4785/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 ALDH1A1 1335/4885SMN1; SMN2 3761/4885MAPT 4440/4885
US-20050267173-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 ALDH1A1 2580/4885SMN1; SMN2 3725/4885MAPT 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback